Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 12;8(6):e65385.
doi: 10.1371/journal.pone.0065385. Print 2013.

Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal

Affiliations

Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal

Andrew J Solomon et al. PLoS One. .

Abstract

Background: Rheumatologic diseases may cause neurologic disorders that mimic multiple sclerosis (MS). A panel of serum autoantibodies is often obtained as part of the evaluation of patients suspected of having MS.

Objectives: To determine, in light of recently revised diagnostic criteria for MS, neuromyelitis optica, and Sjogren's Syndrome, if testing for autoantibodies in patients with a confirmed diagnosis of MS would reveal a frequency or demonstrate a clinical utility divergent from previous reports or lead to identification of undiagnosed cases of Sjogren's Syndrome.

Methods: Convenience sample cross-sectional study of MS patients recruited from the OHSU Multiple Sclerosis Center.

Results: Autoantibodies were detected in 38% (35/91) of patients with MS and were not significantly associated with disease characteristics or severity. While four patients had SSA antibodies, none met diagnostic criteria for Sjogren's Syndrome.

Conclusions: Rheumatologic autoantibodies are frequently found in MS patients and are not associated with disease severity or systemic rheumatologic disease. Our demonstration of the low specificity of these autoantibodies suggests that the diagnostic utility and cost-effectiveness of testing is not supported when there is strong clinical suspicion of MS and low clinical suspicion of rheumatologic disease.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, et al. (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14: 1157–74. - PMC - PubMed
    1. Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, et al. (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 83: 280–91. - PubMed
    1. de Andrés C, Guillem A, Rodríguez-Mahou M, López Longo FJ (2001) Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients. Acta Neurol Scand 104: 83–7. - PubMed
    1. Collard RC, Koehler RP, Mattson DH (1997) Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 49: 857–61. - PubMed
    1. Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, et al. (2007) Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187: 159–65. - PubMed

Publication types